Tags

Type your tag names separated by a space and hit enter

Chronic treatment with the gonadotropin-releasing hormone agonist D-Ser(TBU)6-EA10-LRH for contraception in women and men.
Int J Fertil. 1980; 25(3):239-46.IJ

Abstract

The stimulatory analogue of luteinizing hormone-releasing hormone (LRH) D-Ser(TBU)6-EA10-LRH was administered subcutaneously (sc) or intranasally to 10 women with amenorrhea and to 44 healthy female and male volunteers. The LRH agonist evoked a pronounced initial release of follicle-stimulating hormone (FSH) and luteinizing hormone (LH) but the gonadotropin response decreased during the course of the chronic treatment. Ovulation could not be induced in seven amenorrheic women who were given prolonged treatment with the analogue. In normally ovulating women, ovulation was inhibited during chronic treatment with a daily sc dose of 5 microgram or a daily intranasal dose of 400 microgram. In four healthy men treated with 5 microgram of the LRH agonist daily over 17 weeks basal FSH, LH, and testosterone levels decreased but spermatogenesis and potency were unaffected. The negative effects on testosterone secretion may limit the use of the LRH agonist for male contraception. Chronic intranasal administration of the stimulatory LRH analogue paradoxically inhibited ovulation and proved to be a safe and effective new approach to contraception in women.

Authors

No affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Comparative Study
Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

6108935

Citation

Nillius, S J., et al. "Chronic Treatment With the Gonadotropin-releasing Hormone Agonist D-Ser(TBU)6-EA10-LRH for Contraception in Women and Men." International Journal of Fertility, vol. 25, no. 3, 1980, pp. 239-46.
Nillius SJ, Bergquist C, Wide L. Chronic treatment with the gonadotropin-releasing hormone agonist D-Ser(TBU)6-EA10-LRH for contraception in women and men. Int J Fertil. 1980;25(3):239-46.
Nillius, S. J., Bergquist, C., & Wide, L. (1980). Chronic treatment with the gonadotropin-releasing hormone agonist D-Ser(TBU)6-EA10-LRH for contraception in women and men. International Journal of Fertility, 25(3), 239-46.
Nillius SJ, Bergquist C, Wide L. Chronic Treatment With the Gonadotropin-releasing Hormone Agonist D-Ser(TBU)6-EA10-LRH for Contraception in Women and Men. Int J Fertil. 1980;25(3):239-46. PubMed PMID: 6108935.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Chronic treatment with the gonadotropin-releasing hormone agonist D-Ser(TBU)6-EA10-LRH for contraception in women and men. AU - Nillius,S J, AU - Bergquist,C, AU - Wide,L, PY - 1980/1/1/pubmed PY - 1980/1/1/medline PY - 1980/1/1/entrez KW - Androgens KW - Biology KW - Clinical Research KW - Contraception KW - Contraceptive Agents KW - Contraceptive Agents, Female KW - Contraceptive Agents, Male KW - Contraceptive Mode Of Action KW - Endocrine System KW - Family Planning KW - Follicle Stimulating Hormone--analysis KW - Gonadotropins KW - Gonadotropins, Pituitary KW - Hormone Antagonists--administraction and dosage KW - Hormones KW - Inhibition Of Fertilization KW - Luteinizing Hormone--analysis KW - Men KW - Ovulation Suppression KW - Physiology KW - Pituitary Hormone Releasing Hormones KW - Research Methodology KW - Testosterone--analysis KW - Women SP - 239 EP - 46 JF - International journal of fertility JO - Int J Fertil VL - 25 IS - 3 N2 - The stimulatory analogue of luteinizing hormone-releasing hormone (LRH) D-Ser(TBU)6-EA10-LRH was administered subcutaneously (sc) or intranasally to 10 women with amenorrhea and to 44 healthy female and male volunteers. The LRH agonist evoked a pronounced initial release of follicle-stimulating hormone (FSH) and luteinizing hormone (LH) but the gonadotropin response decreased during the course of the chronic treatment. Ovulation could not be induced in seven amenorrheic women who were given prolonged treatment with the analogue. In normally ovulating women, ovulation was inhibited during chronic treatment with a daily sc dose of 5 microgram or a daily intranasal dose of 400 microgram. In four healthy men treated with 5 microgram of the LRH agonist daily over 17 weeks basal FSH, LH, and testosterone levels decreased but spermatogenesis and potency were unaffected. The negative effects on testosterone secretion may limit the use of the LRH agonist for male contraception. Chronic intranasal administration of the stimulatory LRH analogue paradoxically inhibited ovulation and proved to be a safe and effective new approach to contraception in women. SN - 0020-725X UR - https://www.unboundmedicine.com/medline/citation/6108935/Chronic_treatment_with_the_gonadotropin_releasing_hormone_agonist_D_Ser_TBU_6_EA10_LRH_for_contraception_in_women_and_men_ DB - PRIME DP - Unbound Medicine ER -